ENDV (Endonovo Therapeutics) ROC (Joel Greenblatt) %: 0.00% (As of Jun. 2025)


What is Endonovo Therapeutics ROC (Joel Greenblatt) %?

Endonovo Therapeutics ENDV -99.00% ROC (Joel Greenblatt) % is 0.00% as of Jun. 2025. The stock has 3 warning signs investors should review. Among 1,325 Biotechnology companies, Endonovo Therapeutics ranks worse than 75471.62% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Endonovo Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was 0.00%.

The historical rank and industry rank for Endonovo Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

During the past 13 years, Endonovo Therapeutics's highest ROC (Joel Greenblatt) % was 42175.00%. The lowest was -172676.92%. And the median was -30975.00%.

ENDV's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -297.52
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Endonovo Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.

Endonovo Therapeutics  (OTCPK:ENDV) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.

Endonovo Therapeutics ROC (Joel Greenblatt) % Related Terms

Endonovo Therapeutics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics ROC (Joel Greenblatt) % Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42,175.00 -108,150.00 0.00 0.00 0.00

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ENDV vs RGBP, SIGY, CNBX: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Endonovo Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's ROC (Joel Greenblatt) % falls into.


Endonovo Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.018) - (9.507 + 4.49 + 6.337)
=-20.316

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.018) - (9.815 + 4.714 + 6.337)
=-20.848

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Endonovo Therapeutics for the quarter that ended in Jun. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.996/( ( (0 + max(-20.316, 0)) + (0 + max(-20.848, 0)) )/ 1 )
=-0.996/( ( 0 + 0 )/ 1 )
=-0.996/0
= %

Note: The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 0.00% mean?
Endonovo Therapeutics (ENDV) has a ROC (Joel Greenblatt) % of 0.00% as of Jun. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Endonovo Therapeutics and its competitors. According to the industry distribution chart, Endonovo Therapeutics ranks #999999 out of 1325 companies in the Biotechnology industry.
Is Endonovo Therapeutics' ROC (Joel Greenblatt) % too high?
Endonovo Therapeutics' current ROC (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Endonovo Therapeutics ranks #999999 out of 1325 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Endonovo Therapeutics' ROC (Joel Greenblatt) % compare to RGBP and SIGY?
According to the Biotechnology industry distribution chart, Endonovo Therapeutics ranks #999999 out of 1325 companies for ROC (Joel Greenblatt) %. This places Endonovo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Endonovo Therapeutics and its competitors. Endonovo Therapeutics's current ROC (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current ROC (Joel Greenblatt) % of 0.00%. The current ROC (Joel Greenblatt) % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current ROC (Joel Greenblatt) % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.